Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyd dengue virus serotype 2 live (attenuated) antigen
- Development stage
- Approved
- Lead developer
- Sanofi Pasteur
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Cyd dengue virus serotype 2 live (attenuated) antigen is a component of the tetravalent, chimeric yellow fever–dengue, live-attenuated vaccine known as CYD-TDV or Dengvaxia. This biologic is engineered using a yellow fever virus backbone in which the preM and E genes are replaced by those from dengue virus serotype 2. The mechanism of action involves stimulating the immune system to produce neutralizing antibodies against DENV-2 and other included serotypes, thereby providing protection against subsequent infection. The full tetravalent formulation targets all four major dengue virus serotypes and is indicated for prevention of dengue disease in individuals with prior exposure to the virus[3][4][6]. Sanofi Pasteur developed this vaccine; it has been approved in multiple countries for use in specific age groups[3][8].
- Brand names
- Dengvaxia
- Other names
- CYD-TDVchimeric yellow fever–dengue vaccinetetravalent dengue vaccine component
Beyond the preview
Go deeper on Cyd dengue virus serotype 2 live (attenuated) antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cyd dengue virus serotype 2 live (attenuated) antigen.